Search Results - iBoxes

Play Episode

3min

Proactive - Interviews for investors

Arizona Gold Project yields highest grades for core to Date at Philadelphia Project

Arizona Gold and Silver Vice President of Exploration Greg Hahn spoke with Steve Darling from Proactive to announce a major milestone at the company’s Philadelphia Project in Arizona, reporting the highest gold grades to date from core drilling on the property. The standout result came from drill hole PC25-136, which intersected 4.91 metres grading 9.20 grams per tonne (gpt) gold, highlighting a robust zone of epithermal quartz and calcite-bearing vein breccia within rhyolitic volcanic rocks. Hahn explained that this new high-grade zone, located in the Rising Fawn area, had previously seen limited exploration and lacked the drilling required for a formal resource estimate. The mineralized interval is surrounded by lower-grade stockwork, indicating a broader halo of gold-bearing material. PC25-136 is the first of six drill holes recently completed to test extensions of earlier high-grade intercepts, targeting both down-dip and along-strike mineralization. Hahn noted that the presence of abundant yellow and green quartz in this zone is geologically significant and comparable to mineralization seen in the historic Oatman gold district, suggesting strong potential for further high-grade discoveries. Importantly, this intercept appears to be relatively shallow in the vein system, enhancing the prospectivity as drilling continues to deeper levels. Ongoing drilling at the Philadelphia Project is focused on following up these new results by targeting deeper extensions of the Rising Fawn zone, with the goal of expanding the mineralized envelope and advancing toward a resource definition. #proactiveinvestors #arizonagoldandsilverinc #tsxv #azs #otcqb #azasf #MiningUpdates #GoldExploration #PhiladelphiaProject #MiningDrilling #GoldAndSilver #JuniorMining #ArizonaMining #DrillResults #MiningStocks #PhiladelphiaProject #GregHahn #PreciousMetals #ProactiveInvestors #ResourceExpansion

Proactive - Interviews for investors

Tonix Pharmaceuticals launches :TONIX ONE™ A digital breakthrough in migraine management

Tonix Pharmaceuticals is making waves in the healthcare industry with the launch of TONIX ONE™ a fully integrated digital platform designed to empower migraine patients with better tools for understanding and managing their condition. In an exclusive discussion with Proactive’s Steve Darling, Dr. Seth Lederman, CEO of Tonix Pharmaceuticals, unveiled the platform’s innovative features and strategic partnerships aimed at transforming migraine care. By collaborating with UpScript Telemedicine, ProModRx, Blink Health, and a leading mobile application specializing in disease tracking, symptom reporting, and management, TONIX ONE offers a comprehensive, patient-centric solution. Dr. Lederman highlighted that TONIX ONE™ beyond conventional migraine education by providing critical insights into the limitations of oral medications, which can sometimes result in delayed or ineffective symptom relief. The platform bridges the gap between patients and healthcare providers, offering direct access to migraine specialists via telehealth consultations and seamless e-prescription requests—ensuring a faster, more effective pathway to treatment. With this initiative, Tonix Pharmaceuticals aims to not only educate and empower patients in their treatment journey but also eliminate the barriers to care that many migraine sufferers face. By integrating advanced digital health solutions,TONIX ONE™ stands at the forefront of a new era in migraine management, offering patients greater control over their health and well-being. #proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp #Biotech #MigraineTreatment #TonixOne #DigitalHealth #Telemedicine #ZembraceSymTouch #Tosymra #HealthcareInnovation #PharmaNews #ProactiveInvestors

Proactive - Interviews for investors

Zynex Medical champions noninvasive, non-addictive pain management with NexWave

Zynex Medical Executive Vice President of Sales Steve Fox joined Steve Darling from Proactive to discuss the company’s commitment to noninvasive, non-addictive at-home pain management through its flagship device, NexWave. Fox highlighted how Zynex Medical is tackling the opioid crisis by providing alternative pain solutions that empower both healthcare providers and patients. The NexWave device integrates three key modalities—TENS (Transcutaneous Electrical Nerve Stimulation), IFC (Interferential Current), and NMES (Neuromuscular Electrical Stimulation)—making it a versatile tool for post-operative recovery and long-term pain management. “Most providers are really on board with a device like this because it’s very universal,” Fox explained. A crucial aspect of Zynex’s strategy is education, with nearly 300 sales representatives across the U.S. working to inform healthcare providers about alternatives to opioid prescriptions. While the company’s focus remains on the domestic market, Fox noted significant untapped potential within the United States. Fox also spoke about Zynex’s strong internal culture, emphasizing the team’s alignment around a shared mission. “It’s our mission to provide an at-home pain management treatment option that’s noninvasive, non-addictive. That won’t change,” he said, highlighting the passion and unity that continue to drive the company’s growth. #proactiveinvestors #nasdaq #zyxi #zynexinc #NexWave #PainManagement #OpioidAlternative #MedicalDevices #NonInvasiveTherapy #NMES #TENS #HealthcareInnovation #ProactiveInvestors

Proactive - Interviews for investors

Pluri CEO Yaky Yanay on pioneering cell-tech solutions for global needs

Pluri Inc. (NASDAQ:PLUR) CEO Yaky Yanay joined Proactive's Stephen Gunnion with more about the company’s progress in developing and commercializing its cell-based technology platform, highlighting recent partnerships, strategic financing, and future milestones. Pluri is a biotechnology company focused on manufacturing products derived from cells—including human, animal, and plant cells—for applications across industries such as healthcare, food, and agriculture. "We are taking this tiny organism, cells... and we create products out of them," Yanay explained. A key highlight was Pluri’s collaboration with Hemafund in Ukraine to enhance the country’s preparedness for radiation emergencies. Yanay detailed the use of PLX-R18, a placenta-based therapeutic developed with US federal agencies, which has shown potential to significantly improve survival rates following radiation exposure. The discussion also covered Pluri’s recent financing activities, including a $10 million raise and the acquisition of cacao company Kokomodo. These moves are part of Pluri’s broader expansion into the food sector, addressing shortages in coffee and cacao through cell cultivation in bioreactors. Looking ahead, Yanay emphasized a strong pipeline of deals for 2025, with a focus on sustainable, cell-based solutions for some of humanity’s biggest needs. For more interviews and updates, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications for future content. #PluriInc #BiotechInnovation #CellTherapy #SustainableTech #RadiationPreparedness #CoffeeCrisis #CacaoShortage #HealthcareTech #InvestmentNews #YakyYanay #ProactiveInvestors

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free